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h Abstract
Objective. This cross-sectional study was intended to
assess the association between immunohistochemical
analysis of p16INK4A and fragile histidine triad (FHIT) and
the presence of precancerous cervical lesions.
Materials and Methods. Women seen at Pe´rola Bying-
ton Hospital, Sa˜o Paulo, Brazil, with histologically con-
firmed cervicitis (n = 31), cervical intraepithelial neoplasia
(CIN) 1 (n = 30), CIN 2,3 (n = 30), and cervical cancer (n = 7)
had also cervical material collected for liquid-based
cytology, human papillomavirus Hybrid Capture 2 (HC2)
test, and p16 and FHIT immunohistochemical reactions.
Results. p16 and FHIT reactions were scored as the
following: G1%, 1% to 5%, 95% to 25%, and 925%.
Receiver operating curve analysis was used to select p16
and FHIT score cutoffs for further categorical analyses. All
but one of the 37 CIN 2,3/cancer cases had a p16 score of
greater than 1% to 5%. Among the 61 cervicitis/CIN 1
cases, 46 (75%) had a p16 score lower than 1% to 5%. In
contrast, no association of FHIT expression and severity of
cervical lesions could be demonstrated in this data set.
Receiver operating curve analyses suggested the score of
1% to 5% for p16 as the cutoff that best discriminates CIN
2,3/cancer from cervicitis/CIN 1. No cutoff for FHIT scores
could be suggested with data set.
Conclusions. p16, but not FHIT expression, has the po-
tential to be used as complementary diagnostic tool to
investigate human papillomavirusYinduced cervical
lesions, if these results are confirmed in larger studies. h
Key Words: p16, FHIT, cervical cancer, HPV, liquid-based
cytology
The ambiguity of morphological features to classifycervical lesions and its correct correlation with
prognosis led many investigators to research new
paradigms to assess this information [1, 2].
The major function of p16 protein, a product of
CDKN2A gene, is to suppress the activity of cyclin-
dependent kinase (CDK) 4 and CDK-6. This is an
essential function to be considered in oncology because
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p16 is directly involved with the cell cycle regulation,
because CDK-4 and CDK-6 cyclins regulate the G1
checkpoint [3]. In addition, p16 seems to hamper the
transforming activity of the oncogenic human papillo-
mavirus (HPV) gene E6; even so, E7 interaction with
retinoblastoma protein can directly stimulate cyclin-
inducing cell replication [4]. The effect of this patho-
physiological phenomenon is p16 overexpression, which
is presently accepted as an occurrence linked with the
potential oncogenic activity of HPV infection in cervical
and other genital lesions [3, 5]. Furthermore, p16 is
deemed to be a powerful molecular biomarker for ma-
lignant and premalignant HPV-induced cervical lesions
[6Y8], and overexpression is recognized as a predictor of
poor prognosis [9Y12].
The fragile histidine triad (FHIT) gene encompasses
the common chromosomal fragile site FRA3B. The HPV
has been found to be able to integrate its genes into the
chromosome 3 fragile site of cultured cells, deleting a
piece of DNA that includes the FHIT gene [13]. The
FHIT gene alteration is believed to occur fairly early in
the development of some types of cancer. The FHIT
inactivation seems to be a later event, probably related
to evolution for a more aggressive neoplasia. Thus,
FHIT immunohistochemical expression in premalignant
lesions may give useful diagnostic and prognostic data
[14, 15]. The FHIT gene loss of heterozygosity was
found to be significantly associated with oncogenic HPV
infection, suggesting a link between the integration of
viral DNA and subsequent gene deletion in progression
of cervical cancer. Recently, a microarray comparative
genomic hybridization study has endorsed that FHIT
deletion was the most common DNA losses present in
47% of the invasive carcinomas of the cervix [16].
The objective of our study was to investigate the
association between HPV-induced lesions of the cervix
and immunohistochemical analysis of p16INK4A and
FHIT.
MATERIALS AND METHODS
This was a cross-sectional study performed at Pe´rola
Byington Hospital, Sa˜o Paulo, Brazil, from January
through December 2002. Women with histologically
confirmed cervicitis (n = 31), cervical intraepithelial
neoplasia (CIN) 1 (n = 30), CIN 2,3 (n = 30), and
cervical cancer (n = 7) had cervical material previously
collected for liquid-based cytology (LBC), HPV Hybrid
Capture 2 (HC2) test (Digene Co, Gaithersburg, MD)
for high-risk HPV-DNA and p16 and FHIT immuno-
histochemical reactions (IHRs). p16 and FHIT IHRs
were performed in all but 4 cases in whom FHIT could
not be assessed for technical reasons. All laboratory tests
were processed blindly at the Pathology Division of
Adolfo Lutz Institute. The study protocol was approved
by the institutional review boards of both institutions
involved in the project.
Cytological and Histological Samples
Cervical samples were collected with a scored cervical
brush included in the DNACitoliq LBC kit and stored in
a universal collection medium (both from Digene Brasil,
Sa˜o Paulo, Brazil). Cytology results were reported in
accordance to the Bethesda 2001 system [17]. Histolo-
gical specimens were initially evaluated according to the
World Health Organization [18], blinded to cytological
results.
Immunohistochemistry for p16 and FHIT
The glass slides silane-treated with new 3-Km paraffin
sections obtained for immunohistochemistry (IHC)
analysis was maintained at 55-C for 6 hours. The IHC
procedures were performed after removing paraffin in
xylene and rehydrating baths in decreasing concentra-
tions of ethyl alcohol and in distilled water. Antigen
retrieval was performed using a 10-mmol/L concentra-
tion of citrate buffer (pH 6.0) in a pressure cooker for 10
minutes. The slides were allowed to cool down at room
temperature and then subjected to immunostaining.
The antibodies used in this study were p16INK4A
(dilution, 1:500), obtained from MTM Laboratories
AG (Heidelberg, Germany), and anti-FHIT (polyclonal
rabbit; Zymed Laboratories, San Francisco, CA) (dilu-
tion, 1:2000), suppliedbyDakoAS (Glostrup,Denmark),
both amplified by Envision peroxidase system (Dako
Cytomation, Carpinteria, CA). The color of immuno-
staining was generated by chromogenic substrate diami-
nobenzidine (100 mg%, Sigma D5637 AQ2), and hydrogen
Table 1. p16 IHR Scores According to Histopathological
Results
p16
Histology
TotalCervicitis/CIN 1 CIN 2,3/cancer
Negative (G1%) 36 0 36
1%Y5% 10 1 11
95%Y25% 9 3 12
925% 6 33 39
Total 61 37 98
IHR, immunohistochemical reaction; CIN, cervical intraepithelial neoplasia.
W2 G 0.0001.
2 & L O N G AT T O - F I L H O E T A L .
Copyright @ 2007 American Society for Colposcopy and Cervical Pathology. Unauthorized reproduction of this article is prohibited.
peroxide (0.1%). After light counterstaining in Harry
hematoxylin, the slides were mounted with Entellan
medium (Merck, Darmstadt, Germany) and analyzed
using light microscopy.
Evaluation of the IHRs
Evaluation of p16INK4A IHR staining was scored, as
published elsewhere [5]. Positive nuclear and cytoplas-
mic positive reactions were scored as follows: negative
(no reaction or G1% of positive cells), sporadic (G5%
isolated positive cells), focal (between 5% and 25%
positive cells), and diffuse (925% positive cells). A
similar scoring system was applied to evaluate cytoplas-
mic FHIT IHR.
Hybrid Capture Test
The HC2 test was performed in accordance with the
recommendations of the manufacturer (Digene Co) and
reported in relative light units (RLU). Results were
categorized as high (RLU, 920), intermediate (RLU,
5Y19.9), and low (RLU, 1Y4.99) [19]. Only high-risk
HPV was tested.
Table 2. Fragile Histidine Triad IHR Scores According
to Histopathological Resultsa
FHIT
Histology
TotalCervicitis/CIN 1 CIN 2,3/cancer
Negative (G1%) 3 6 9
1%Y5% 10 6 16
95%Y25% 23 10 33
925% 23 13 36
Total 59 35 94
IHR, immunohistochemical reaction; FHIT, fragile histidine triad; CIN, cervical
intraepithelial neoplasia.
W2 = 0.37.
aFHIT expression was not available in 4 patients.
Figure 1. Receiver operating curve of the different p16 cutoffs to diagnose CIN 2,3/cancer lesions.
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Statistical Analysis
The magnitude of p16 and FHIT association with histo-
logical results was compared by means of the Pearson W2
test. McNemar W2 test was used to compare p16 and
FHIT scores with LBC results. For statistical analysis
purposes, cytology results were lumped in 2 broad
categories: cervicitis/CIN 1 and CIN 2,3/cancer. Simi-
larly, histological examination results were also grouped
as normal/CIN 1 or CIN 2,3/cancer categories. p16 and
FHIT cutoffs that better discriminate CIN 2,3/cancer
lesions were determined by the receiver operating
characteristic curveAQ3 (ROC) analyses. Cutoffs that maxi-
mized the areas under the curve were used to categorize
p16 and FHIT scores in subsequent categorical analyses;
p values of less than .05 were considered significant.
Data were stored and analyzed using the SPSS statistical
software, version 13.0 (SPSS Inc, Chicago, IL).
RESULTS
Of the 37 histologically confirmed CIN 2,3/cancer cases
included in the study, the result of LBC was abnormal in
34 cases (91.9%). The HC2 test turned out positive in all
CIN 2,3/cancer cases. All but one of the 37 CIN 2,3/
cancer cases had a p16 score of greater than 1% to 5%
( T1Table 1). Among the 61 cervicitis/CIN 1 cases, 46
(75%) had a p16 score lower than 5%. In contrast, as it
can be seen in T2Table 2, there was no significant
association between FHIT scores and type of cervical
lesion. Results of the ROC analyses shown in F1Figures 1
and F22 AQ4suggest the score of 1% to 5% for p16 as the
cutoff that best discriminate CIN 2,3/cancer lesions
from cervicitis/CIN 1 lesions. However, no cutoff for
FHIT scores could be suggested with this data set. The
1% to 5% cutoff for p16 score ( T3Table 3) has a sensitivity
Figure 2. Receiver operating curve of the different FHIT cutoffs to diagnose CIN 2,3/cancer lesions.
Table 3. p16 IHR Scores Using the 1% to 5% Cutoff
in Relation to Histological Examination Results AQ5
p16
Histology
TotalCIN 2,3/cancer Cervicitis/CIN 1
91%Y5% 36 15 51
G1% 1 46 47
Total 37 61 98
IHR, immunohistochemical reaction; CIN, cervical intraepithelial neoplasia.
W2 G 0.00001; odds ratio = 111.1; 95% CI = 14.2Y1,000.
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of 97.3%, specificity of 75.4%, positive predictive value
of 70.6%, and negative predictive value of 97.9% for
identifying CIN 2,3/cancer.
F3 Figures 3 andF4 4 illustrate p16 and FHIT IHRs in CIN
2,3 cases.
DISCUSSION
The p16INK4A, and FHIT immunohistochemical expres-
sions were evaluated in a series of biopsy-proven cervical
lesions. The results have shown that 97.3% of CIN 2,3/
cancer cases had a p16 score of 1% to 5% or more,
whereas LBC was reported as CIN 1 positive in 91.9%.
The FHIT expression did not significantly correlate with
high-grade lesions. The HC2 test for high-risk HPV
turned out positive in 100% of CIN 2,3/cancer cases.
New molecular players have emerged in the cancer
scenario; as a consequence, a number of interesting data
are now available [20]. Among all recent feasible
technical options, p16 IHC has been purposed as an
alternative to optimize the recognition of HPV infection
with potential of progression [20]. According to the data
presently observed, p16INK4AAQ6 expression in cervical
high-grade lesions showed a sensitivity of 97.3% and a
negative predictive value close to 100% because all but
one of the 37 CIN 2,3/cancer cases had p16INK4A score
of greater than 1% to 5%. In addition, 75% (46/61) of
cervicitis/CIN 1 cases had a p16 score lower than 1% to
5%. These data strongly indicate that p16 expression
increases with the severity of cervical lesions that
corroborate, in part, the diagnostic potential of
p16INK4A evaluation [21]. The optimism with this
marker is justified based on the progressive intensity of
p16 expression in minor lesions (cervicitis/CIN 1) to
severe ones (CIN 2 and CIN 3), as herein demonstrated.
However, the caveat is that the positive predictive value
of p16 test for identifying CIN 2,3/cancer of 70.6%
found in this study with 37.7% of diseased cases will be
less impressive in populations with lower prevalence of
cases AQ7. In addition, if p16INK4A has had an unambiguous
performance in paraffin-embedded tissues, the same
could not be observed in cytological samples. Indeed, the
results are not so clear-cut when p16 expression is
assessed in cytological samples. Actually, the conten-
tious findings in cytological preparations strongly limit
the use of p16INK4A under routine conditions [22].
Currently, when the combination of HPV HC2 test and
LBC is the backbone of prevention of cervical high-
grade lesions [23], the controversial results of p16INK4A
should be judiciously ascertained in further studies with
larger series to validate the data obtained with biopsy
samples [22].
On the other hand, in this series, FHIT immunohis-
tochemical score in CIN 2,3/cancer cases (65.7%) was
unexpectedly greater than 1% to 5%. In contrast, other
studies provided evidence indicating that FHIT expres-
sion seems to be a good prognostic marker [14Y16]. The
loss of FHIT gene in HPV-induced lesions is believed to
represent a powerful option to predict cervical disease
progression mainly in cigarette smokingYassociated
cervical carcinogenesis [24]. However, the mechanisms
of FHIT inactivation and the real meaning of FHIT gene
methylation in cervical cancer are not sufficiently
understood. For this reason, caution is suggested in its
use as a functionally relevant biomarker for cervical
Figure 3. p16-positive reaction in CIN 2,3 cervical lesion (original
magnification, 20).
Figure 4. Fragile histidine triad positive reaction in CIN 2,3
cervical lesions (original magnification, 20).
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cancer [25]. The IHR performed with the commercially
available antibody for FHIT is somewhat equivalent to
FHIT protein expression, but its specificity should be
confirmed by subsequent immunoblot analysis because
of potential false-positive results [25]. This fact can
explain, in part, the lack of specificity of FHIT
immunoreaction in the present series. Certainly, it is
supposed that best results have been reported with the
use of the original antiYFHIT-glutathione S-transferase
fusion antibody [26]. Even so, there are data obtained
with this original antibody that clearly demonstrated
ubiquitous distribution of aberrant FHIT expression in
all types of cervical lesions, including cancer [27],
similar to those reported in the present work with
commercially FHIT antibody. Importantly, ROC analy-
sis could not identify a cutoff of FHIT expression that
could adequately discriminate CIN 2,3 from cervicitis/
CIN 1 lesions in this study.
Finally, p16INK4A and FHIT markers have theoretical
and interesting differences because of their apparently
opposing expressions during cervical lesion develop-
ment, which warrants additional investigation. Re-
cently, cohypermethylation of p16 and FHIT genes
was demonstrated to be a helpful biomarker for pre-
dicting the recurrence-associated prognosis of nonsmall
lung cancer [28].
In a large study involving more than 200,000 women
of the Kaiser Permanente Health Maintenance Organi-
zation [29], positive HPV HC2 test together with nor-
mal cytology was found in 3% of the women. Diagnostic
accuracy in this clinical situation is likely to improve
with the assessment of p16INK4A, but not FHIT ex-
pression, if further well-controlled studies corroborate
the results herein presented.
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